Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.

Autor: Spanjaart AM; Department of Hematology, Amsterdam UMC location University of Amsterdam, Cancer Center Amsterdam and LYMMCARE, Amsterdam, The Netherlands., Ljungman P; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge and Karolinska Comprehensive Cancer Center, Stockholm, Sweden., Tridello G; European Society for Blood and Marrow Transplantation (EBMT) Data Office, Department of Medical Statistics & Bioinformatics, Leiden, Netherlands., Schwartz J; European Society for Blood and Marrow Transplantation (EBMT) Leiden Study Unit, European Society for Blood and Marrow Transplantation (EBMT) Data Office, Leiden, Netherlands., Martinez-Cibrián N; Department of Hematology, Hospital Clínic, Barcelona, Spain., Barba P; Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain., Kwon M; Department of Hematology, Hospital G. Universitario Gregorio Marañon, Institute of Health Research Gregorio Marañon, Madrid, Spain., Lopez-Corral L; Department of Hematology, Hospital Universitario de Salamanca and IBSAL, Salamanca, Spain., Martinez-Lopez J; Department of Hematology, Hospital Univ. 12 de Octubre, Complutense University, CNIO, Madrid, Spain., Ferra C; Clinical Hematology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Barcelona, Spain., Di Blasi R; Department of Hematology, Assistance Publique Hôpitaux de Paris-Hopital Saint-Louis, Paris, France., Ghesquieres H; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France., Mutsaers P; Department of Hematology, Erasmus MC Cancer Center, Rotterdam, the Netherlands., Calkoen F; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Jak M; Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands., van Doesum J; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Vermaat JSP; Department of Hematology, Leiden University Medical Center, Leiden, Netherlands., van der Poel M; Department of Hematology, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands., Maertens J; Deptartment of Hematology, University Hospital Gasthuisberg, Leuven, Belgium., Gambella M; Department of Hematology and Cellular Therapy, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Metafuni E; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica e Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Ciceri F; Hematology and BMT Unit IRCCS San Raffaele Scientific Institute, Milan, Italy., Saccardi R; Cell Therapy and Transfusion Medicine Unit Azienda Ospedaliero Universitaria Careggi, Firenze, Italy., Nicholson E; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Tholouli E; Department of Clinical Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK., Matthew C; Adult HSCT unit, Northern Centre for Bone Marrow Transplantation, Newcastle Tyne, UK., Potter V; King's College Hospital NHS Foundation Trust, Department of Haematological Medicine, Denmark Hill, London, UK., Bloor A; Adult Leukaemia and Bone Marrow Transplant Unit, Christie NHS Foundation Trust Hospital, University of Manchester, Manchester, UK., Besley C; Department of Haematology, University Hospitals Bristol and Weston NHSFT, Bristol, UK., Roddie C; Department of Haematology, University College London Hospital, London, UK., Wilson K; Blood and Bone Marrow Transplantation Department, University Hospital of Cardiff, Cardiff, UK., Nagler A; Chaim Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel., Campos A; Celular Therapy Department, Instituto Portugués de Oncologia do Porto, Francisco Gentil, E.P.E, Porto, Portugal., Petersen SL; Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Folber F; Department of internal Medicine, Hematology and Oncology, Masaryk University Hospital Brno, Brno, Czech Republic., Bader P; Department for Children and Adolescents, Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany., Finke J; Department of Hematology/Oncology/Stem Cell Transplantation, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg im Breisgau, Germany., Kroger N; Department of Stem cell Transplantation, University Hospital Eppendorf, Hamburg, Germany., Knelange N; European Society for Blood and Marrow Transplantation (EBMT) Leiden Study Unit, European Society for Blood and Marrow Transplantation (EBMT) Data Office, Leiden, Netherlands., de La Camara R; Department of Hematology, Hospital Universitario de La Princesa, Madrid, Spain., Kersten MJ; Department of Hematology, Amsterdam UMC location University of Amsterdam, Cancer Center Amsterdam and LYMMCARE, Amsterdam, The Netherlands., Mielke S; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Department of Laboratory Medicine, Karolinska Institutet and University Hospital, Karolinska Comprehensive Cancer Center, Karolinska ATMP Center, Stockholm, Sweden. stephan.mielke@ki.se.; Cellular Therapy and immunobiology working party (CTIWP) of EBMT, . stephan.mielke@ki.se.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2024 Sep; Vol. 38 (9), pp. 1985-1991. Date of Electronic Publication: 2024 Jul 23.
DOI: 10.1038/s41375-024-02336-1
Abstrakt: COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT. One-hundred-eighty patients were included in the analysis, 39 diagnosed in 2020, 35 in 2021 and 106 in 2022. The median age was 58.9 years (min-max: 5.2-78.4). There was a successive decrease in COVID-19-related mortality over time (2020: 43.6%, 2021: 22.9%, 2022: 7.5%) and in multivariate analysis year of infection was the strongest predictor of survival (p = 0.0001). Comparing 2022 with 2020-2021, significantly fewer patients had lower respiratory symptoms (21.7% vs 37.8%, p = 0.01), needed oxygen support (25.5% vs 43.2%, p = 0.01), or were admitted to ICU (5.7% vs 33.8%, p = 0.0001). Although COVID-19-related mortality has decreased over time, CAR T-cell recipients remain at higher risk for complications than the general population. Consequently, vigilant monitoring for COVID-19 in patients undergoing B-cell-targeting CAR T-cell treatment is continuously recommended ensuring optimal prevention of infection and advanced state-of-the art treatment when needed.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: